Aura Biosciences, Inc. (AURA) intrinsic value & 10-year financials
Aura Biosciences, Inc. (AURA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $6.10
- Market cap
- $368.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -215.6%
- Free cash flow (FY2025)
- -$85.2M
AURA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$106.2M | -$1.76 | -$85.2M | — | -99.2% |
| FY2024 | — | -$86.9M | -$1.75 | -$81.1M | — | -56.9% |
| FY2023 | — | -$76.4M | -$1.93 | -$64.6M | — | -57.9% |
| FY2022 | — | -$58.8M | -$1.96 | -$55.7M | — | -126.3% |
| FY2021 | — | -$35.3M | -$1.49 | -$34.5M | — | -975.9% |
| FY2020 | — | -$22.2M | — | -$25.1M | — | 22.6% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aura Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aura Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -54.6% ROIC.
Aura Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Aura Biosciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.